Meridian Clinical Research - Savannah
Welcome,         Profile    Billing    Logout  
 4 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bradley, Paul
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
GMRx2_PCT, NCT04518306: Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Completed
3
295
Europe, US, RoW
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo
George Medicines PTY Limited
Hypertension
09/23
10/23
GMRx2_ACT, NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Completed
3
1385
Europe, US, RoW
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg ., telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg
George Medicines PTY Limited
Hypertension
08/23
09/23
NCT06374394: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Recruiting
3
850
Europe, US
RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
12/24
05/25
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
US
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
US
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Active, not recruiting
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
11/24
NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Active, not recruiting
1/2
1015
US
31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™
Vaxcyte, Inc.
Pneumococcal Vaccines
09/24
09/24
NCT05477186: Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Completed
1
180
US, RoW
CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (75 μg), CV0501 (100 μg), CV0501 (150 μg), CV0501 (200 μg)
GlaxoSmithKline
COVID-19, SARS-CoV-2
08/23
08/23

Download Options